Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

13th Asia-Pacific Oncologists Annual Meeting

Kualalumpur, Malaysia

Chieko Kai

Chieko Kai

University of Tokyo, Japan

Title: A Novel Oncolytic Modified Measles Virus Is A Promising Candidate For Cancer Therapy

Biography

Biography: Chieko Kai

Abstract

Oncolytic virus therapy is a promising therapy for various tumor types. We previously reported that a wild-type measles virus (MV) efficiently infects and shows high oncolytic activity to breast cancer cells. Since wild type MV infects immune cells using signaling lymphocyte activation molecule (SLAM) as a receptor, and causes its pathogenicity in host animals, we generated a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAM blind lost infectivity to lymphoid cells, but maintained its infectivity to breast cancer cells using another receptor of MV, PVRL4 (poliovirus receptor related-4)/Nectin-4. Nectin-4 is hardly expressed in other tissues except placenta in healthy adults. Recent studies reported that Nectin-4 expression is up-regulated in various types of tumor cells, including breast cancer and non-small-cell lung cancer, which is the leading cause of cancer-related death. We examined the efficacy of rMV-SLAMblind on various cell lines derived from refractory cancers, in which Nectin-4/PVRL4 was expressed. The virus showed high oncolytic activity against them and also effectively suppressed tumor mass growth in xenotransplanted immunodeficient mice. Thus, rMV-SLAMblind should be a promising candidate of a novel therapeutic agent for caner treatment.